To compare the effectiveness and safety profiles of corticosteroids versus standard therapy in alleviating diabetic retinopathy among Chinese patients with uncontrolled diabetes. Chinese diabetes patients aged more than 18 years with diabetic retinopathy were enrolled. Subjects who met the eligibility criteria were enrolled and were given either corticosteroid (Dexamethasone 1mg Intravenously or Intramuscularly per day in divided doses every 12 hours) or standard therapy (Ranibizumab 0.5-mg monthly injection) for 2 months. A total of 200 enrolled patients completed the study. Compared to Ranibizumab group, patients treated with Dexamethasone had almost similar proportion of eye with complete resolution (86% vs 85%, p>0.005) and similar improvement in height of subretinal fluid was observed in Dexamethasone- treated patients as compared to Ranibizumab-treated patients (91.2[32.4] vs 94.5 [27.4]; p>0.005). Patients treated with Ranibizumab had slightly greater improvement in lesion size, central macular thickness, bestcorrected visual acuity as compared to Dexamethasone, however, the difference was not statistically significant. Overall, the results of the present study suggested that efficacy of Ranibizumab was almost similar to Dexamethasone in diabetic retinopathy among Chinese patients with uncontrolled diabetes. Ranibizumab was numerically more effective than Dexamethasone in Chinese diabetes patients with retinopathy. However, both study drugs were statistically similar with respect to the results of primary and secondary efficacy endpoints.